Influenza Virus Non-Structural Protein 1 (NS1) Disrupts Interferon Signaling by Jia, Danlin et al.
Influenza Virus Non-Structural Protein 1 (NS1) Disrupts
Interferon Signaling
Danlin Jia
1, Ramtin Rahbar
1, Renee W. Y. Chan
2,3, Suki M. Y. Lee
3, Michael C. W. Chan
3, Ben Xuhao
Wang
1, Darren P. Baker
4, Bing Sun
5, J. S. Malik Peiris
3, John M. Nicholls
2, Eleanor N. Fish
1,6*
1Department of Immunology, University of Toronto, Toronto, Canada, 2Department of Pathology, University of Hong Kong, Hong Kong, People’s Republic of China,
3Department of Microbiology, University of Hong Kong, Hong Kong, People’s Republic of China, 4Biogen Idec Inc., Cambridge, Massachusetts, United States of America,
5Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, People’s Republic of China, 6Division of Cell and Molecular Biology, Toronto
General Research Institute, University Health Network, Toronto, Canada
Abstract
Type I interferons (IFNs) function as the first line of defense against viral infections by modulating cell growth, establishing
an antiviral state and influencing the activation of various immune cells. Viruses such as influenza have developed
mechanisms to evade this defense mechanism and during infection with influenza A viruses, the non-structural protein 1
(NS1) encoded by the virus genome suppresses induction of IFNs-a/b. Here we show that expression of avian H5N1 NS1 in
HeLa cells leads to a block in IFN signaling. H5N1 NS1 reduces IFN-inducible tyrosine phosphorylation of STAT1, STAT2 and
STAT3 and inhibits the nuclear translocation of phospho-STAT2 and the formation of IFN-inducible STAT1:1-, STAT1:3- and
STAT3:3- DNA complexes. Inhibition of IFN-inducible STAT signaling by NS1 in HeLa cells is, in part, a consequence of NS1-
mediated inhibition of expression of the IFN receptor subunit, IFNAR1. In support of this NS1-mediated inhibition, we
observed a reduction in expression of ifnar1 in ex vivo human non-tumor lung tissues infected with H5N1 and H1N1 viruses.
Moreover, H1N1 and H5N1 virus infection of human monocyte-derived macrophages led to inhibition of both ifnar1 and
ifnar2 expression. In addition, NS1 expression induces up-regulation of the JAK/STAT inhibitors, SOCS1 and SOCS3. By
contrast, treatment of ex vivo human lung tissues with IFN-a results in the up-regulation of a number of IFN-stimulated
genes and inhibits both H5N1 and H1N1 virus replication. The data suggest that NS1 can directly interfere with IFN signaling
to enhance viral replication, but that treatment with IFN can nevertheless override these inhibitory effects to block H5N1
and H1N1 virus infections.
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Introduction
Transcriptional activation of IFNs-a/b is rapidly initiated in
response to detection of viral-derived factors by cellular pattern
recognition receptors [1]. IFNs-a/b subsequently bind their cognate
cell surface receptor, leading to the activation of the receptor-
associated kinases, Jak1 and Tyk2 [2]. Signal transducers and
activators of transcription (STAT) proteins are recruited to the
receptor, phosphorylated on tyrosine residues by these Jaks, then
releasedfromthereceptortoformtranscriptionfactorcomplexesthat
translocate into the nucleus and upregulate the expression of IFN-
stimulated genes (ISG). IFN signaling can be negatively regulated by
members of the suppressors of cytokine signaling (SOCS) family.
SOCS1 has been shown to block IFN signaling through direct
physical binding with Jak1, whereas SOCS3 and CIS can interact
with the phosphorylated receptor to prevent the recruitment and
phosphorylation of downstream mediators like STAT proteins [2].
Given the critical role of IFNs-a/b as a first line of defense
against infection, it is not surprising that many viruses have
evolved strategies to block an IFN response as a means to increase
their replication efficiency [2,3]. Viral-mediated inhibition of IFNs
can be generalized into three categories, including disruption of
IFN induction, disruption of IFN-inducible signaling and disrup-
tion of IFN-mediated effector functions.
The non-structural protein 1 (NS1) of influenza A viruses exerts
its inhibitory effects on IFN predominately by interfering with IFN
production [4]. NS1 disrupts the induction of IFNs by first
inhibiting the intracellular sensor RIG-I, which plays a critical role
in detecting ssRNA during influenza A virus infection [5]. RIG-I
activation leads to association with the downstream adaptor IPS-1,
resulting in phosphorylation of IRF3 and subsequent transcrip-
tional activation of IFN-b [5,6]. Experimental evidence suggests
that NS1 can associate with RIG-I, as well as TRIM25, a
ubiquitin ligase required for RIG-I activation, to prevent its
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translocation and NFkB activation are impaired in the presence of
NS1, which in turn blocks the induction of proinflammatory
cytokines and IFNs [9,10]. In addition, NS1 can interfere with
host mRNA splicing and polyadenylation by interacting with U6
snRNA and the cleavage polyadenylation specificity factor 30
(CPSF30), respectively. Notably, in addition to inhibition of IFN-b
gene transcription, NS1 promotes the accumulation of IFN-b pre-
mRNA transcripts [11].
NS1 can activate phosphoinositide 3-kinase (PI3K) by interact-
ing with the regulatory subunit, p85, through a putative SH2-
binding domain. Activation of PI3K by NS1 leads to the
downstream activation of Akt, and delays apoptosis of influenza
virus-infected cells [12,13]. Given that NS1 has been shown to
modulate intracellular signaling events and inhibit the induction of
IFN, we undertook experiments to determine whether avian
H5N1 influenza NS1 can also influence facets of IFN-a/b-
inducible signaling. In addition, as more influenza A viruses,
including the highly pathogenic avian H5N1 strain and the
circulating swine origin H1N1 pandemic 2009 strain (S-OIV,
H1N1pdm) are developing resistance to the antiviral agents
oseltamivir and/or the adamantine derivatives, there is an urgent
need for alternative antiviral therapies [14,15,16]. Accordingly we
examined the therapeutic potential of the synthetic IFN-a, IFN
alfacon-1, as an antiviral against H5N1 and H1N1 influenza A
infections, employing a novel human non-tumor lung tissue
explant model.
We provide evidence that expression of H5N1 NS1 reduces
IFN-inducible phosphorylation of STAT proteins and results in
decreased formation of downstream STAT:DNA complexes. We
attribute this NS1-medited inhibition of IFN-inducible signaling to
the effects of NS1 on restricting the cell surface expression of IFN
receptor expression, and also upregulation of the signaling
inhibitors SOCS1 and SOCS3. We provide evidence that
treatment of human lung tissue with IFN alfacon-1 inhibits both
H1N1 and H5N1 viral replication, overriding the inhibitory effects
of NS1.
Materials and Methods
Cells and reagents
The human cervical carcinoma cell line HeLa was obtained
from ATCC (Manassas, VA). Cells were cultured in Dulbecco’s
modified Eagle’s medium (Invitrogen), supplemented with 10%
fetal calf serum (FCS), 100 U/mL penicillin, 100 mg/mL strepto-
mycin (Invitrogen). Plasmids pBudCE4.1 and pBudCE4.1-H5N1
NS1-HA (A/Duck/Hubei/L-1) were kindly provided by Dr. Bing
Sun. Monocyte-derived macrophages were produced, as described
previously [17]. Fresh lung biopsies were obtained from non-
tumor lung tissue obtained during surgical resection of lung tissue
at Queen Mary Hospital in Hong Kong. Written, informed
consent was obtained from all patients and institutional approval
was granted by The Hong Kong University and Hospital
Authority (Hong Kong West) Institutional Review Board. The
biopsies or tissue fragments were excess to the requirements of
clinical diagnosis. Lung tissue from each donor was cut into
multiple fragments (2–3 mm). The tissues were immediately
placed into culture medium (F-12K nutrient mixture with L-
glutamine, and antibiotics) and infected with either influenza A
H5N1 (A/Vietnam/3046/04 or A/HK/483/97) or H1N1 (A/
HK/54/98 or A/Ca/04/09 (H1N1pdm)) viruses within three
hours of collection. Virus was adsorbed for one hour at 37uC, then
free virus was removed by washing the tissue fragments in warm
PBS. Biopsies with no virus added were used as controls. The
biopsy or tissue fragments were incubated at 37uC for the
indicated times.
Human recombinant IFN alfacon-1 (IFN alfacon-1, specific
activity, 6610
8 U/mL) was provided by Three Rivers Pharmaceu-
ticals (Pittsburgh, PA). Human IFN-b (IFN b-1a, specific activity,
1.2610
7 U/mL) was provided by BiogenIdec Inc., Cambridge,
MA. Antibodies against p-STAT1, p-STAT2, p-STAT3, STAT1,
STAT3, HA, SOCS1, and SOCS3 were purchased from Cell
signaling. Antibodies against STAT2 and b-actin were obtained
from Santa Cruz Biotechnology (Santa Cruz, CA).
Transfection and virus infections
Cells (2610
5) were transfected using Lipofectamine LTX
(Invitrogen, CA) according to the manufacturer’s protocol. Briefly,
cells were seeded in 6 well plates 24 hours before transfection.
Plasmid DNA and transfection reagent were mixed in serum-free
medium and incubated for 30 minutes at room temperature.
Transfection complexes were then gently added into individual
wells of the 6-well plate.
For influenza A infection of primary lung tissues, virus was used
at a titer of 1610
7.3TCID50/mL for H5N1, 1610
6.4TCID50/mL
for A/HK/54/98 H1N1 and 1610
7TCID50/mL for pandemic
A/Ca/04/09 H1N1. Human monocyte-derived macrophages
were infected with A/HK/483/97 H5N1 or H1N1 at an MOI
of 2, or mock infected.
Measurements of viral infectivity
The extent of viral infection was determined using a TCID50
(50% tissue culture infectious doses per mL) assay. Briefly, a
confluent 96-well plate of MDCK cells was prepared one day prior
to the viral titration. Cells were then washed with PBS and
overlayed with serum-free Minimum Essential Medium (MEM)
supplemented with 100 U/mL penicillin and 100 mg/mL strep-
tomycin and 2 mg/mL of TPCK (tosylsulfonyl phenylalanylchlor-
omethyl ketone) treated trypsin. 1:10 serial dilutions of stock virus
were adsorbed onto the plates in quadruplicate. The plates were
observed for cytopathic effect daily. The end-point of viral dilution
leading to CPE in 50% of inoculated wells was estimated using the
Karber method [18].
Immunoblotting and immunoprecipitation
Cells were lysed in 30 mL of lysis buffer (1% Triton X-100,
0.5% Nonidet P-40, 150 mM NaCl, 10 mM Tris-HCl, pH 7.4,
1 mM EDTA, 1 mM EGTA, 0.2 mM phenylmethylsulfonyl
fluoride). Protein concentration was determined using the Bio-
Rad protein DC assay kit (Bio-Rad Laboratories, Hercules, CA).
30 mg of protein lysate/sample was denatured in 56 sample
reducing buffer and resolved by SDS-PAGE. The separated
proteins were transferred to a nitrocellulose membrane followed
by blocking with 5% bovine serum albumin (w/v) in TBS-T for
1 h at room temperature. Membranes were probed with the
indicated specified antibodies. Proteins were visualized using the
ECL detection system (Pierce, Rockford, IL). For immunoprecip-
itation assays, cells transfected with vector alone or with H5N1
NS1 plasmid were incubated in hypotonic lysis buffer containing
10 mM HEPES, pH 7.4 for 30 minutes on ice, and the suspension
was then briefly sonicated. The suspension was centrifuged at
14000 rpm for 30 min at 4uC. The supernatant was collected and
protein concentration measured using the Bio-Rad protein assay
kit. 500 mg of protein was incubated with 1 mg of either anti-
STAT1 antibody, anti-STAT2 antibody or IgG isotype control
antibody. Antibodies were immunoprecipitated with protein A/G-
Sepharose beads (Santa Cruz Biotechnology) and washed 6 times
NS1 Interferon Signaling
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reducing buffer and resolved by SDS-PAGE.
Cell sorting and flow cytometric analysis for IFNAR1 and
IFNAR2 cell surface expression
24 hours post-transfection, cells were first washed with PBS and
subsequently incubated with Versene for 15 minutes. Suspended
cells were collected and centrifuged at 1500 rpm for 5 minutes.
Cell pellets were then resuspended at 1610
7 cells/mL in 2% FCS.
5610
5 GFP
+ sorted cells were incubated with either anti-human
IFNAR1 (BiogenIdec)[19] or anti-human IFNAR2 antibody
(Caltag), followed by PE-conjugated anti-mouse IgG antibody.
As isotype controls, cells were incubated with PE-labeled isotype
control IgG antibody (eBioscience). All analyses were performed
using the FACS Calibur and CellQuest software. Cells were gated
based on forward and side scatter.
RNA extraction and cDNA synthesis
Cells were lysed using buffer RLT + b-mercaptoethanol with
Qiagen QIA-shredder columns. RNA isolations were carried out
using Qiagen RNeasy mini kits, according to the manufacturer’s
protocol, with DNA digestion. Total cellular RNA was eluted in
RNase-free water. The concentration of RNA was determined by
UV spectrophotometry at 260 nm wavelength (Beckman). cDNAs
were synthesized using 0.5 mg RNA and oligo-dT primers and
Superscript III reverse transcriptase according to the manufactur-
er’s protocol (Invitrogen, CA).
Real-time polymerase chain reaction (RT-PCR)
Real-time PCR was carried out using a LightCyclerH (Roche) in
conjunction with LightCyclerHFastStart DNA Master SYBR
Green PLUS I Kits (Roche). Reactions were carried out in
20 mL volumes containing 4 mL Master SYBR Green PLUS buffer
at a final concentration of 1X, 5 mL of 0.1 mg/mL cDNA. 9 mLo f
PCR-grade water and 1 mL of each 20 mM forward and reverse
primers. PCR reactions were carried out under the following
conditions: pre-incubation at 95uC for 10 minutes, followed by 45
amplification cycles of denaturation for 10 seconds, annealing for
5 seconds at 60uC, extension at 72uC for 10 seconds, melting curve
analysis at 65uC for 15 seconds and a continuous acquisition mode
of 95uC with a temperature transition rate of 0.1uC/s. The data
were subsequently analyzed using software RealQuant. PCRs
were carried using the following primers:
Ifnar1
(forward) 59CACTGACTGTATATTGTGTGAAAGCCAGAG39
(reverse) 59 CATCTATACTGGAAGAAGGTTTAAGTGATG 39
Ifnar2
(forward) 59 ATTTCCGGTCCATCTTATCAT 39
(reverse) 59ACTGAACAACGTTGTGTTCC 39
Influenza A m gene
(forward) 59 CTTCTAACCGAGGTCGAAACG 39
(reverse) 59 GGCATTTTGGACAAAGCGTCTA 39
Isg15
(forward) 59 TCCTGGTGAGGAATAACAAGGG 39
(reverse) 59 CTCAGCCAGAACAGGTCGTC 39
pkr
(forward) 59 GCCTTTTCATCCAAATGGAATTC 39
(reverse) 59 GAAATCTGTTCTGGGCTCATG 39
2959-oas
(forward) 59 AGCTTCATGGAGAGGGGCA 39
(reverse) 59 AGGCCTGGCTGAATTACCCAT 39
socs1
(forward) 59 TTGCCTGGA ACCATGTGG 39
(reverse) 59 GGTCCTGGCCTCCAGATACAG 39
socs3
(forward) 59 GGAGTTCCTGGACCAGTACG 39
(reverse) 59 TTCTTGTGCTTGTGCCATGT 39
b-actin
(forward) 59ACATGGAGAAAAATCTGGCAC 39
(reverse) 59 GTAGCACAGCTTCTCCTTAATGT 39
Electrophoretic mobility shift assay
10 mg of nuclear protein from untreated or IFN-treated cells
was extracted as described previously [20]. Extracts were
incubated with 1 mg poly(dI-dC)poly(dI-dC) for 10 minutes at
4uC in buffer containing 60 mM EGTA, and 5% Ficoll (final
volume 30 mL). 40,000 counts per minute (cpm) of radiolabeled
sis-inducible element (SIE) (59 AGCTTCATTTCCCG-
TAAATCCCT 39) were added and the reaction mixture was
incubated for an additional 20 minutes at ambient temperature.
Protein-DNA complexes were resolved on a 4.5% polyacrylamide
gel using 0.56 TBE (final concentration 45 mM Tris borate,
1 mM EDTA) as the running buffer. Gels were dried and exposed
to autoradiographic film (Kodak BioMax MS) overnight at
280uC. A supershift assay to identify specific STAT:SIE
complexes was carried out prior to EMSA by incubating nuclear
extracts with 2 mg of anti-STAT1 (C-136X (batch #s L1004,
B0403), Santa Cruz Biotechnology) or anti-STAT3 (H-190X,
Santa Cruz Biotechnology; 9132, Cell Signaling Technology)
antibodies for 30 minutes prior to addition of the radiolabeled SIE
for a further 20 minutes.
Immunohistochemistry and confocal microscopy
Cells transfected with H5N1 NS1 plasmid were stained as
described previously [21]. Various proteins were visualized using
fluorescence-conjugated secondary antibodies (Alexafluor-488:
green, Alexafluor-555: red and Alexafluor-647: blue) (Amersham
Biosciences, Cardiff, UK). Images were collected using an upright
Leica SP2 confocal laser-scanning microscope (Leica Microsys-
tems Heidelberg GmbH, Mannheim, Germany), a 1006 oil
immersion lens (1.4 numerical aperture), and a 46digital zoom.
Laser excitations were 488 nm (Ar/Kr) and 543 nm (He/Ne),
attenuated to 10% and 50%, respectively, by way of an acoustic-
optical transmission filter. Sequential scan mode was used to
eliminate cross talk of detected signals, which were filtered
between 500 to 530 nm and 560 to 660 nm. Image resolution
was 512 dpi by 512 dpi (12 bit), and line averaging (46) was used.
Optical sections were collected at 0.5 mm intervals through the
entire cell.
To stain for influenza nucleoprotein, lung tissue explants were
fixed in 10% neutral buffered formalin and processed for paraffin
embedding and immunohistochemistry using a mouse anti-
influenza nucleoprotein antibody (HB65, EVL Laboratories, The
Netherlands).
Results
H5N1 NS1 expression inhibits IFN-inducible STAT
phosphorylation
To investigate the effects of H5N1 NS1 expression on IFN
signaling, HeLa cells were transfected with either vector alone or
plasmid containing HA-tagged H5N1 NS1. 24 hours post-
transfection, cells were treated with IFN-b (1610
3 U/mL) to
promote IFN-inducible signaling. In contrast to cells transfected
with vector alone, there was a notable reduction in IFN-inducible
STAT1, STAT2 and STAT3 phosphorylation in cells express-
ing H5N1 NS1 (Figure 1A). Human lung epithelial A549 cells
NS1 Interferon Signaling
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inducible STAT1 phosphorylation (data not shown).
To confirm that the inhibition of IFN-inducible STAT
phosphorylation is a consequence of NS1 expression, in an
identical series of transfection experiments, cells were fixed and
stained with both anti-phospho-STAT2 and anti-HA (NS1)
antibodies. Confocal microscopy revealed that, in contrast to cells
lacking H5N1 NS1 expression, that exhibit strong IFN-inducible
phospho-STAT2 staining in their nuclei, there is a notable
reduction in IFN-inducible phospho-STAT2 staining in H5N1
NS1-expressing cells (Figure 1B).
NS1 inhibits IFN-inducible STAT-DNA binding
STAT proteins, once activated by phosphorylation, form
functional homo- or hetero-dimeric complexes that migrate to
the nucleus and target specific promoter elements to initiate
transcriptional activation. To examine the functional consequence
of H5N1 NS1-mediated inhibition of IFN-inducible STAT
phosphorylation, we examined STAT-DNA binding, using
electrophoretic mobility shift assay (EMSA) studies. HeLa cells
were transfected with empty vector or vector containing cDNA
encoding H5N1 NS1 for 24 hours, then cells were either left
untreated or treated with IFN-b. Nuclear extracts were prepared
and incubated with a radiolabeled sis-inducible element (SIE),
then resolved by agarose gel electrophoresis to determine the
formation of IFN-inducible STAT:SIE complexes. In contrast to
cells transfected with empty vector, we observed a reduction in the
characteristic STAT1:1:SIE, STAT1:3:SIE, and STAT3:3:SIE
complexes in the presence of H5N1 NS1 protein (Figure 2). In
further support of a functional consequence of NS1-mediated
inhibition of IFN-inducible STAT phosphorylation, the effects of
NS1 on IFN-inducible STAT2 activation were evident as reduced
nuclear phospho-STAT2, described in Figure 1B.
H5N1 and H1N1 infection affect IFNAR expression
Given the effects of NS1 on IFN-inducible activation of STATs,
we next examined the influence of NS1 expression on upstream
molecules involved in IFN signaling, namely the receptors,
IFNAR1 and IFNAR2. HeLa cells were transfected with vector
expressing GFP or a plasmid that co-expresses NS1 and GFP.
GFP-positive cells were FACS sorted 24 hours post-transfection
and analyzed for surface IFNAR1 and IFNAR2 expression using
flow cytometry. Cells expressing H5N1 NS1 exhibited a reduced
level of surface IFNAR1 when compared to cells expressing vector
alone (Figure 3A). Notably, cell surface IFNAR2 expression was
not affected by the expression of NS1. In a subsequent series of
experiments we confirmed that this reduction in cell surface
IFNAR1 expression was restricted to cells expressing NS1
(Figure 3B). To determine whether the differential surface
expression of IFNAR1 and IFNAR2 in the presence of H5N1
NS1 is a consequence of regulation at the mRNA level, HeLa cells
were transfected with either vector-GFP or the NS1-GFP plasmid
as above, and GFP-positive cells were FACS sorted 24 hours
following transfection for subsequent RNA analysis. Ifnar1 and
ifnar2 gene expression were analyzed using RT-PCR. In contrast
to vector-GFP transfected cells, we observed a reduction in ifnar1
but not ifnar2 gene expression in cells transfected with H5N1 NS1
(Figure 3C).
Within the lung, both pneumocytes as well as macrophages are
targets for H5N1 and H1N1 infection. Accordingly, in the next
series of experiments we employed human monocyte-derived
macrophages to examine the effects of both H5N1 and H1N1
virus infections on IFNAR expression. We found that both ifnar1
and ifnar2 were upregulated in response to H1N1 and H5N1
viruses within 6 hours post-infection compared to mock infection
(Figure 4A, B), but that by 24 hours, there was a reduction of both
ifnar1 and ifnar2 compared to mock infection (Figure 4C),
To investigate if inhibition of either ifnar1 or ifnar2 occurs in the
context of influenza A infection in the intact lung, human lung
explant tissues were infected with either H1N1 or H5N1 influenza
A viruses. 18 hours post-infection, RNA was collected and
analyzed. Infection with both viruses led to a selective reduction
in ifnar1 gene expression when compared to mock-infected control
tissues (Figure 4D). Notably, infection with the H5N1 influenza A
strain led to a greater reduction in ifnar1 gene expression
compared to infection with H1N1 virus. The modest inhibitory
effects of H1N1 and H5N1 infection on ifnar2 gene expression
were not statistically significant.
H5N1 and H1N1 regulate SOCS expression
To determine the effect of H5N1 NS1 on negative regulators of
type I IFN signaling, namely SOCS proteins, HeLa cells were
transfected with plasmid containing the H5N1 ns1 gene and
24 hours post-transfection protein extracts were processed and
analyzed for SOCS1 and SOCS3 protein expression. In contrast
to cells transfected with vector alone, we observed an increase in
SOCS1 but not SOCS3 protein in cells expressing H5N1 ns1
(Figure 5A). Interestingly, when we examined the gene expression
profile of socs1 and socs3 in cells that co-express GFP and NS1, we
observed a two-fold increase in both socs1 and socs3 gene
expression when compared to control cells that express GFP
alone (Figure 5B). Moreover, RT-PCR analysis of infected human
lung tissue explants revealed that both socs1 and socs3 gene
expression was upregulated by H5N1 infection, whereas only socs1
gene expression was increased by H1N1 infection (Figure 5C).
IFN treatment upregulates IFN sensitive genes and
inhibits H5N1 and H1N1 influenza A replication in
primary human lung cells
In the next series of experiments, using the non-tumor human
lung explant tissues, we examined the effects of an IFN-a, namely
IFN alfacon-1, on H5N1 and H1N1 influenza A infection. Human
lung explant tissues were pretreated with IFN-alfacon-1 for
16 hours prior to infection with H5N1 or H1N1 influenza A
viruses. At different time points post infection, RNA was extracted
for cDNA synthesis. Analysis of influenza A m gene expression
revealed that IFN alfacon-1 treatment effectively inhibits H5N1
and H1N1 influenza A replication (Figure 6A). Gene expression
analysis for 2959-oas, pkr and isg15, IFN-stimulated genes (ISGs)
associated with an IFN-inducible antiviral response, revealed that
the expression levels for these ISGs were not upregulated in H5N1
or H1N1 virus infected tissues. However, their expression was
upregulated in both H5N1 and H1N1 virus infected human lung
tissue treated with IFN alfacon-1 (Figure 6B).
In a final series of experiments we examined the effects of IFN
alfacon-1 on pandemic H1N1 influenza A infection, when IFN
was added post-challenge with virus. Three different human lung
explants were infected with H1N1pdm virus, then 24 hours post-
infection treated with 1.2610
4 U/ml IFN alfacon-1. At 24 and
48 hours post-treatment, the effects of IFN on viral replication
were evaluated by measuring m gene expression and TCID50
values. The results in Figure 7, panels A and B, provide evidence
for the protective effects of IFN treatment, even when added
postinfection, as assessed by TCID50 and m gene expression. These
results are supported by evidence of a reduction in Influenza A
nucleoprotein expression, visualized in the IFN-treated lung
explants (Figure 7C).
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PLoS ONE | www.plosone.org 4 November 2010 | Volume 5 | Issue 11 | e13927Figure 1. H5N1 NS1 expression inhibits IFN-inducible STAT phosphorylation. A) HeLa cells transfected with vector alone ( ) or HA-tagged
NS1 plasmid (&) were left untreated (2) or treated (+) with IFN-b (16103 U/mL) for 15 mins, 24 hr post-transfection. Cells were harvested, lysates
were resolved by SDS-PAGE and immunoblotted with the indicated anti-phospho-STAT1, anti-phospho-STAT2, anti-phospho-STAT3 and anti-HA(NS1)
antibodies. Membranes were stripped and reprobed with anti-STAT1, anti-STAT2, anti-STAT3 and anti-b-tubulin antibodies as loading controls.
Relative fold induction of phosphorylated STAT proteins was calculated using signal intensity of phospho-STATs over total STATs and normalized
with untreated, vector transfected cells. The data plots are representative of three independent experiments. B) HeLa cells transfected with HA-
tagged NS1 plasmid were treated with IFN-b (1610
3 U/mL) for 15 mins. Cells were then fixed and stained for HA (red) and phospho-STAT2 (blue), and
analyzed by confocal microscopy as described in Materials and Methods. The white arrow identifies the nuclear predominance of NS1and the broken
line in the middle panel defines the nucleus showing reduced phospho-STAT2. Data are representative of two independent experiments.
doi:10.1371/journal.pone.0013927.g001
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Prompted by an increase of oseltamivir-resistant influenza A
virus isolates, this study was initiated to determine the effect of
NS1 on IFN signaling, and to explore the therapeutic potential of
IFN to override any NS1-mediated inhibitory effects. Any IFN
response is augmented by a positive feedback loop; specifically,
IFN produced in response to virus infection binds to and activates
IFNAR, leading to gene induction, which includes IFN. Thus IFN
exerts both direct and paracrine effects on producer and adjacent
cells. Previous studies indicate that H5N1 is able to overcome this
feedback loop and the NS1 of H5N1 has been implicated in the
development of this resistance [22].
Herein we report novel strategies by which the H5N1 influenza
virus NS1 alters IFN-a/b signaling, mediated by the inhibition of
IFNAR and SOCS protein expression. The inhibitory effects of
NS1 on IFNs-a/b have largely been attributed to its ability to
inhibit IFN induction. A number of viruses have evolved to target
STAT proteins and block the antiviral activity of IFNs:
Paramyxoviruses such as SV5 and type II human parainfluenza
viruses (HPIV2) block IFN signaling through their V proteins,
which induce proteasomal degradation of STAT1 and STAT2 by
polyubiquitation [23]. HCV core proteins block STAT1 activation
and subsequent function, mediated by STAT1-core protein
interactions and suppression of STAT1 gene expression [24].
We provide evidence that expression of the H5N1 influenza virus
NS1 in HeLa cells leads to a reduction of IFN-inducible STAT
phosphorylation (Figure 1).
The phosphorylation-dependent activation of STAT1 and
STAT2 is critical for mediating IFN-inducible antiviral responses
[25]. Activated STAT proteins form various complexes that
subsequently translocate into the nucleus to initiate gene
expression via binding to specific elements in the promoter regions
of ISGs. In the absence of these transcriptional effector proteins,
cells are unresponsive to IFNs and are highly susceptible to viral
infection [26,27]. The inhibition of IFN-inducible phosphorylation
of STATs in the presence of H5N1 NS1 resulted in a reduction in
the formation of the characteristic STAT1:1:SIE, STAT1:3:SIE
and STAT3:3:SIE complexes (Figure 2).
These results prompted us to evaluate whether NS1 might affect
upstream effectors of the STATs, thereby limiting their IFN-
inducible phosphorylation and activation. FACS and confocal
microscopy analysis of surface IFNAR1 and IFNAR2 expression
revealed a reduction in cell surface IFNAR1 in the presence of
H5N1 NS1, yet IFNAR2 surface expression remained unaltered
(Figure 3). Based on the ability of NS1 to inhibit host mRNA
generation, we examined NS1 effects on ifnar1 and ifnar2 gene
expression, and showed that after an initial, early increase in ifnar1
and ifnar2 expression, likely reflective of an innate cellular
response, there was a reduction in both ifnar1 and ifnar2 expression
in monocyte-derived macrophages by 24 hours, but a more
selective reduction in expression of ifnar1 in ex vivo lung tissues by
16 hours, once viral replication became fully established (Figure 4).
This NS1-dependent reduction in ifnar1 gene expression is likely
responsible for the decrease in IFN-inducible STAT phosphory-
lation and DNA binding. The basal level of expression of distinct
signaling effectors, including IFNAR1, JAK1, TYK2, IRF9 and
STAT2, has been shown to correlate directly with the intensity of
an IFN response [28]. IFNAR1 null cells are completely non-
responsive to IFN treatment and mice null for IFNAR1 are,
likewise, unresponsive to IFNs-a/b and highly susceptible to
microbial infections [29]. Clinical studies of HCV patients whom
are either non-responders or exhibit a reduced sensitivity to IFN
therapy, identified a reduction in either ifnar1 or ifnar2 gene
expression when compared to IFN responders [30]. Polymor-
phisms in the promoter region of ifnar1 and ifnar2 have been
Figure 2. H5N1 NS1 expression inhibits IFN-inducible STAT:SIE complex formation. A) HeLa cells transfected with either vector alone or
HA-tagged NS1 plasmid were left untreated (2) or treated (+) with IFN-b (1610
3 U/mL) for 15 mins, 24 hr post-transfection. Nuclear extracts were
isolated and equal amounts of protein were incubated with
32P-labeled SIE probe. Complexes were resolved by native gel electrophoresis and
visualized by autoradiography. Data are representative of two independent experiments. HeLa cells were treated with IFN-b (1610
3 U/mL) for
15 mins. Nuclear extracts were isolated and equal amount of protein were incubated with
32P-labeled SIE probe in the presence or absence of 2 mgo f
anti-STAT1 and anti-STAT3 antibodies, as indicated. Complexes were resolved by native gel electrophoresis and visualized by autoradiography.
doi:10.1371/journal.pone.0013927.g002
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malaria, multiple sclerosis, trypanosomaiasis, HCV and HIV
[31,32,33,34]. In contrast, over-expression of IFNAR1 and
IFNAR2, as is the case in Down’s Syndrome patients, where
chromosome 21 is trisomic, results in an enhanced sensitivity to
IFN [35].
While the specific mechanism by which H5N1 NS1 downreg-
ulates IFNAR1 expression requires further investigation, NS1 will
inhibit pre-mRNA splicing, polyadenylation and nuclear export.
NS1 interacts with components of the splicing machinery, U6
snRNA, which complex with other constituents of the spliceosome
to mediate pre-mRNA splicing [11]. An association between NS1
and U6 snRNA hinders its ability to complex with other catalytic
subunits of the spliceosome, thereby leading to the accumulation
of pre-mRNAs in the nucleus of the host cell. Additionally, NS1
affects polyadenylation of host mRNA through targeting of
CPSF30 and PABII [36,37]. 39 cleavage and polyadenylation of
mRNAs promotes their export into the cytoplasm, whereas
mRNAs that have undergone 39 cleavage alone are retained in
the nucleus [38]. Viewed together, the inhibitory effect of
influenza virus H5N1 NS1 on ifnar1 gene expression is an effective
mechanism to render target cells insensitive to IFN and overrides
the initial non-specific antiviral effect of IFNAR upregulation seen
in the monocyte derived macrophages.
IFNs-a/b are not only critical components of the innate
immune response, but also play a prominent role in modulating an
adaptive immune response. IFNs-a promote the differentiation
and maturation of dendritic cells (DCs), which subsequently
present viral peptide in the context of the major histocompatibility
complex (MHC) to activate T cells. Additionally, IFNs-a/b can
modulate co-stimulatory molecule expression, to further stimulate
or prime virus-specific CD4
+ and CD8
+ T cells. During influenza
A virus infection, expression of NS1 in DCs blocks their
maturation and subsequently results in ineffective T cell activation
[39]. NS1 expression in DCs alters the expression of numerous
genes that are required for both maturation and migration,
including ifnar1 [39].
Notably, infection with the H5N1 influenza A strain led to a
greater reduction in ifnar1 gene expression compared to infection
with H1N1 virus (Figure 4C, D) in the ex vivo lung tissue model.
Figure 3. H5N1 NS1 reduces surface IFNAR1 but not IFNAR2 expression. A) HeLa cells were transfected with either GFP vector alone (green)
or GFP vector containing HA-tagged NS1 (red), then 24 hr post-transfection, GFP-positive cells were FACS sorted and stained for IFNAR1 or IFNAR2
and analyzed by FACS. Data are representative of three independent experiments. B) HeLa cells were transfected with HA-tagged NS1 plasmid and
24 hr post-transfection were fixed and stained for HA (green) and either IFNAR1 (red; upper panel) or IFNAR2 (red; lower panel), and analyzed by
confocal microscopy. Data are representative of two independent experiments. C) HeLa cells were transfected with either GFP vector alone ( ) or GFP
vector containing HA-tagged NS1 (&). 24 hr post-transfection, GFP positive cells were FACS sorted, RNA extracted and cDNA synthesized. Ifnar1,
ifnar2 and b-actin gene expression were analyzed by RT-PCR. Gene expression was calculated relative to b-actin gene expression and normalized to
cells transfected with GFP vector alone. Data are representative of two independent experiments. Significant differences (asterisk) were determined
by Student’s t-test (p,0.05).
doi:10.1371/journal.pone.0013927.g003
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pathogenic H5N1 influenza A virus exhibits structural differences
in both the RNA-binding and effector domains when compared to
NS1 from other influenza strains. H5N1 NS1 can associate with
itself to form a novel tubular oligomeric structure, whereas NS1
from other strains adopt a dimeric conformation [40,41]. These
conformational differences may contribute to the different degrees
of inhibition of ifnar1 gene expression observed between H5N1
and H1N1.
SOCS proteins are potent inhibitors of JAK/STAT signaling.
There is accumulating evidence that influenza virus infection will
also inhibit an IFN response in part through up-regulation of
SOCS1 and/or SOCS3 expression [42,43]. SOCS1 inhibits IFN
signaling through direct physical interactions with JAK1, whereas
SOC3 and CIS interact with the phosphorylated receptor to
hinder the recruitment and phosphorylation of downstream
effectors such as STATs [44,45]. Over-expression of SOCS1
and/or SOCS3 will effectively reduce IFN responses through the
inhibition of STAT phosphorylation and induction of ISGs [46].
Many viruses, including respiratory syncytial virus, herpesviruses
and hepatitis C virus, modulate SOCS1 expression to inhibit
STAT activation as a way to suppress an IFN response [47,48,49].
Our data revealed that both socs1 and socs3 gene expression
increased in HeLa cells expressing H5N1 NS1, yet we were only
able to detect an increase in SOCS1 protein expression (Figure 5).
SOCS1 expression can be induced by various cytokines in a tissue-
specific manner [50,51]. STAT proteins including STAT1 and
STAT5 have been suggested to play a role in mediating the
transcriptional activation of socs gene expression upon cytokine
stimulation [50,51]. Studies in breast cancer cells suggest that
MAP kinase (MAPK) p38 activation, an intermediate effector in
MAPK signaling, may also play a role in upregulating SOCS1
expression. The hyperinduction of proinflammatory cytokines in
H5N1 but not H1N1 influenza A-infected primary human
macrophages was strongly associated with p38 activation,
suggesting a possible mechanism for the induction of SOCS1
expression [52,53,54]. Notably, SOCS1 expression is regulated at
the translational level in a cap-dependent manner by the
eukaryotic initiation factor 4E-binding proteins [55]. NS1 affects
cellular translation by interacting with eIF4G and activating the
PI3K pathway [12,13,56,57]. Activation of PI3K can lead to
translational activation through mTOR and subsequent phos-
Figure 4. Influenza virus infection reduces ifnar1 and ifnar2 expression at 24 hours post-infection in human monocyte-derived
macrophages and ex vivo lung tissues. Human monocyte-derived macrophages were infected with A/HK/483/97 H5N1 or A/HK/54/98 H1N1
virus (Multiplicity of Infection (MOI) =2). RNA was extracted from the cells at A) 3 hr, B) 6 hr, and C) 24 hr post-infection. Following cDNA synthesis,
ifnar1 (&) and ifnar2 ( ) expression was assayed by real-time PCR. Data shown are fold induction of gene expression relative to mock-infected control
after normalizing to b-actin in each sample. Representative data of duplicate experiments with means of triplicate assays are shown; D) Human lung
explant tissue was either mock-infected (PBS) or infected with A/HK/483/97 H5N1 or A/HK/54/98 H1N1 influenza A viruses, as described in Materials &
Methods. 18 hr post-infection tissue was processed to extract RNA. cDNA was synthesized and expression of ifnar1, ifnar2 and b-actin gene
expression was measured by RT-PCR analysis. Gene expression was calculated relative to b-actin gene expression and normalized to mock infected
tissues. Data are representative of two independent experiments. Significant differences (asterisk) were determined by Student’s t-test (p,0.05).
doi:10.1371/journal.pone.0013927.g004
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dependent mRNA translation [58].
The adamantine derivatives, amantadine and rimantadine, as
M2 ion channel-blockers were the first antivirals licensed for use
against influenza A viruses [59], yet all isolates of the pandemic
H1N1 2009 are resistant to both amantadine and rimantadine
[60]. There are two other drugs licensed globally for specific
treatment and prevention of influenza. Relenza (zanamavir) was
Figure 5. NS1 regulates SOCS1 and SOCS3 expression. A) HeLa cells were transfected with vector alone or HA-tagged NS1 plasmid, then 24 hr
post-transfection cells were harvested and lysates were resolved by SDS-PAGE and immunoblotted with the indicated anti-SOCS1 and anti-SOCS3
antibodies. Membranes were probed with anti-HA antibody to confirm expression of NS1, and anti-tubulin antibody was applied as a loading control.
Relative fold induction of proteins was calculated using signal intensity over loading and normalized against vector transfected cells (SOCS1 , SOCS3
&). Data are representative of two independent experiments. B) HeLa cells were transfected with either GFP vector alone ( ) or GFP vector containing
HA-taggedNS1(&).24 hrpost-transfection,GFP
+cellsweresorted,RNAextractedandcDNAsynthesized.Geneexpressionofsocs1( ),socs3 (&)andb-
actin gene expression were analyzed by RT-PCR. Gene expression was calculated relative to b-actin gene expression and normalized to cells transfected
with GFP vector alone. Data are representative of two independent experiments. C) RNA from human lung tissue either mock-infected (PBS) or infected
with A/HK/54/98 H1N1 or H5N1 influenza A viruses was collected 18 hr post-infection. cDNA was synthesized and expression of socs1(&), socs3(&) and
b-actin gene expression was measured by RT-PCR analysis. Gene expression was calculated relative to b-actin gene expression and normalized to mock
infected cells. Data are representative of two independent experiments. Significant differences (asterisk) were determined by Student’s t-test (p,0.05).
doi:10.1371/journal.pone.0013927.g005
NS1 Interferon Signaling
PLoS ONE | www.plosone.org 9 November 2010 | Volume 5 | Issue 11 | e13927Figure 6. Treatment with IFN alfacon-1 inhibits H5N1 and H1N1 replication in primary human lung cells and upregulates ISG
expression. Different human surgical lung tissue explants (1–6) were either left untreated (¤) or treated with IFN alfacon-1 (1.26104 U/mL) (#) for
16 hr. Tissues were then infected with H5N1 (1–4) or H1N1 influenza A viruses (5, 6), as indicated. At different time points post infection, RNA from
cells was collected and cDNA synthesized. Gene expression for A) influenza A m gene, was measured by RT-PCR. Gene expression for B) pkr ( ), isg15
(&), 2959-oas ( ), and b-actin, was measured by RT-PCR analysis at 18 hr post-infection with H5N1 or A/HK/54/98 H1N1 for explant 5. Data are
representative of two independent experiments and normalized to mock infected controls.
doi:10.1371/journal.pone.0013927.g006
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PLoS ONE | www.plosone.org 10 November 2010 | Volume 5 | Issue 11 | e13927Figure 7. Treatment with IFN alfacon-1 inhibits pandemic H1N1 2009 virus replication in human lung tissue. Three different human
surgical lung tissue explants were infected with pandemic H1N1 2009 virus for 24 hr, then either left untreated (&) or treated with IFN alfacon-1
(1.26104 U/mL) ( ) for a further 48 hr. At the indicated times A) Viral titers (TCID50) and B) Influenza A m gene expression were measured; Significant
differences were determined by Student t-test: * , p,0.05; ** , p,0.01. C) Thin sections of infected human lung explants, either untreated (i) or
IFN-treated (ii) were stained for influenza A nucleoprotein (pink).
doi:10.1371/journal.pone.0013927.g007
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the influenza virus NA complexed with its substrate, sialic acid
[61]. Tamiflu (oseltamivir) was subsequently developed, based on
the structure of Relenza [62]. Relenza has poor bioavailability, it
must be delivered topically and is administered by means of an
inhaler, which delivers drug to the upper respiratory tract, the
primary site of virus replication. Substitution of the glycerol side
chain with a hydrophobic side chain enables Tamiflu to be orally
available. Tamiflu is taken in an encapsulated form as a prodrug,
which is activated by liver esterases to form the active drug [63].
Although the pandemic H1N1 2009 virus is sensitive to
oseltamivir, resistance has been detected in isolated clinical cases
in Hong Kong, Denmark, Japan and Canada [64]. For H5N1
virus, reports of drug resistance in approximately 2% of adult
patients and 18% of pediatric patients infected, raises concerns
[65].
In both guinea pig and ferret models, IFN-a treatment
effectively inhibits both H1N1 and H5N1 viral replication
[22,66], though multiple doses appear necessary in the guinea
pig model. Viewed together with the evidence we provide for
the antiviral effects of IFN against H1N1 and H5N1 in the human
lung explant tissue model, we infer that despite the inhibitory
mechanisms employed by NS1 to target an IFN response, IFN
treatment can override these effects (Figure 6). Notably, IFN
treatment was inhibitory against both H5N1 and H1N1 influ-
enza A strains, including the pandemic H1N1 influenza 2009.
Moreover, we provide evidence that IFN treatment post-challenge
with virus is effective at limiting viral replication: human lung
explants when infected with H1N1pdm exhibited IFN-inducible
reduction in viral titer, M gene and influenza nucleoprotein
expression. Given the broad spectrum antiviral activities of IFNs,
that are not pathogen-specific, development of resistance is
avoided. Accordingly, in ongoing studies we are evaluating the
safety profile and therapeutic potential of IFN alfacon-1 treatment
in individuals infected with influenza-like illness, specifically
pandemic H1N1pdm.
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